With a thousand new Covid-19 cases reported every hour, there is growing concern about how protected some vaccinated Americans are against the highly contagious Delta variant.
new one laboratory study Online posts on Tuesday have raised some concerns that the one-dose Johnson & Johnson vaccine is not as strong at fighting disease from coronavirus variants, including the delta variant, as the two-dose mRNA shots.
An average of 10,000 to 40,000 new cases have been reported in the US daily since the start of the month, according to data from Granthshala News. At least 13 million people in the US have received a single dose of Johnson & Johnson — but experts say people shouldn’t rush to boost their Johnson & Johnson vaccinations with another shot.
For full coverage of the COVID-19 pandemic
In the study, which has not been peer-reviewed or published in any medical journal, researchers at the NYU Grossman School of Medicine compared how well two doses of mRNA vaccines from Pfizer-BioNtech and Moderna differed. For a single dose of Johnson & Johnson vaccine. In a laboratory experiment, researchers compared a small number of blood samples from 10 people who received the Johnson & Johnson vaccine and 17 people who received the Pfizer or Moderna shots. The results suggested the Johnson & Johnson vaccine may be less effective against some types of anxiety.
According to the researchers, the study only looked at the antibody response in the blood samples. Other important components of the immune response, such as T cells that can protect the body from viruses, were not investigated.
Earlier this month, researchers in South Africa reported their real-world data about health care workers who received a single-dose vaccine. The research, which has yet to be published, showed that, overall, more than 90 percent of success infections were mild.
Last week, researchers at Beth Israel Deaconess Medical Center in Boston found in a laboratory setting that the antibody response from the Johnson & Johnson vaccine worked well against the delta variant and that the immune response lasted for eight months. research, published in the New England Journal of Medicine, Johnson & Johnson was assuring the millions of people receiving the vaccine.
In a statement Tuesday, Johnson & Johnson responded that the new research does not show “the full nature of immune protection.”
download nbc news app For full coverage of the COVID-19 pandemic
On “The Beat With Ari Melber” Wednesday on MSNBC, National Institute of Allergy and Infectious Diseases director Dr. Anthony Fauci said lab samples from the new study showed antibody levels lower than a single dose of the Johnson & Johnson shot. compared to two-dose vaccines, but it is important to wait for clinical data to determine the effect on people receiving the Johnson & Johnson vaccine and whether they are getting sick.
“We don’t have clinical data that matches a [vaccine] against the other,” Fauci said. “We need to wait for the clinical data. If the clinical data reflects the lab data, you have to reevaluate.”
I got the Johnson & Johnson vaccine. What should I do?
“I wouldn’t worry,” said Dr., an infectious disease specialist and chair of the Department of Global Health at Emory University in Atlanta. Carlos Del Rio said. “If I start seeing people hospitalized who have gotten J&J, I think that’s going to tell me something. At this time, I don’t see any evidence that J&J is safer than other vaccines. is less.
A spokeswoman for the Centers for Disease Control and Prevention said the NYU research is just one study of the vaccine’s effectiveness. The agency’s position on the booster still stands: “Americans who have been fully vaccinated no booster shot needed This time.”
Will COVID-19 Boosters Be Necessary?
Fauci told a Senate hearing on the US response to COVID on Tuesday that studies are being conducted to determine whether boosters – the third dose of mRNA vaccines or the second dose of the Johnson & Johnson vaccine – can increase protection against the variant. will be required. or less likely to have immunity.
“We don’t want people to believe that when you’re talking about boosters it means that the vaccines are not effective,” he said. “They are highly effective.”
On Thursday, the CDC’s Vaccine Advisory Committee will discuss booster shots, especially for people with weakened or compromised immune systems. They are the people most likely to be first in line for booster shots when they become available.
Credit: www.nbcnews.com /